Edition:
United States

Biofrontera AG (B8FGn.F)

B8FGn.F on Frankfurt Stock Exchange

4.03EUR
24 Mar 2017
Change (% chg)

€-0.09 (-2.12%)
Prev Close
€4.11
Open
€4.00
Day's High
€4.03
Day's Low
€3.90
Volume
8,130
Avg. Vol
27,573
52-wk High
€4.87
52-wk Low
€2.14

B8FGn.F

Chart for B8FGn.F

About

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and... (more)

Overall

Beta: 0.05
Market Cap(Mil.): €150.68
Shares Outstanding(Mil.): 37.76
Dividend: --
Yield (%): --

Financials

  B8FGn.F Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -0.32 -- --
ROI: -327.25 -2.56 13.01
ROE: -- 5.14 14.16

BRIEF-Biofrontera: positive prelim results for primary endpoint of Phase III clinical trial (Ameluz)

* Reported on Monday it receives positive preliminary results for the primary endpoint of its Phase III clinical trial evaluating the safety and efficacy of its topical drug BF-200 ALA (Ameluz) in combination with daylight photodynamic therapy (PDT)

Feb 07 2017

BRIEF-Biofrontera: European Commission extends Ameluz approval to basal cell carcinoma

* European Commission extends Ameluz approval to basal cell carcinoma Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 30 2017

BRIEF-Biofrontera: European Commission provides unlimited approval for Ameluz

* European Commission provides unlimited approval for Ameluz Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 29 2016

BRIEF-Biofrontera: 49,990 subordinate convertible debentures fully placed

* Bond issue: 49,990 subordinate convertible debentures fully placed Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 24 2016

BRIEF-Biofrontera: capital increase 5,012,950 new shares fully placed

* Capital increase: 5,012,950 new shares fully placed Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 17 2016

BRIEF-Biofrontera receives binding commitments from investors for EUR 14.8 mln

* Receives commitments regarding the acquisition of new shares and convertible bonds

Nov 01 2016

BRIEF-Biofrontera resolves on capital increase and issue of convertible bonds

* Said on Monday resolves on capital increase and issue of convertible bonds

Nov 01 2016

BRIEF-Biofrontera: 12-month follow-up results of phase III trial evaluating Ameluz for BCC

* Biofrontera Announces 12-month Follow-up Results Of Phase III Trial Evaluating Ameluz For BCC

Oct 20 2016

BRIEF-Biofrontera initiates U.S. commercial launch of Ameluz for actinic keratosis

* Initiates U.S. commercial launch Of Ameluz for actinic keratosis Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 18 2016

More From Around the Web

Earnings vs. Estimates